2
|
Cespón-Fernández M, Raposeiras-Roubín S, Abu-Assi E, Manzano-Fernández S, Flores-Blanco P, Barreiro-Pardal C, Castiñeira-Busto M, Muñoz-Pousa I, López-Rodríguez E, Caneiro-Queija B, Cobas-Paz R, Fernández-Barbeira S, Domínguez-Erquicia P, Domínguez-Rodríguez LM, López-Cuenca Á, Gómez-Molina M, Baz-Alonso JA, Calvo-Iglesias F, Valdés-Chávarri M, Íñiguez-Romo A. Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study. Am J Cardiovasc Drugs 2019; 19:487-495. [PMID: 30924021 DOI: 10.1007/s40256-019-00343-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
INTRODUCTION The goal of this study was to determine the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and follow-up heart failure (HF) according to left ventricular ejection fraction (LVEF) in patients with acute myocardial infarction (AMI). METHODS This cohort study used a retrospective registry of 8169 consecutive patients discharged with a diagnosis of AMI from two university hospitals in Spain between 2010 and 2016. We used a multivariable competing risk analysis, survival-time inverse probability weighting (IPW) propensity score adjusting, and propensity score matching (PSM) to investigate the association between ACEI/ARB treatment and follow-up HF. RESULTS During the follow-up (3.3 ± 2.2 years), 1296 patients were admitted for HF (5.2 per 100 person-years). ACEI/ARB use was not associated with fewer follow-up HF admissions in patients with LVEF > 40% (univariate analysis: sub-hazard ratio [sHR] 1.10; 95% confidence interval [CI] 0.95-1.27; p = 0.197; IPW adjusting analysis: sHR 1.11; 95% CI 0.95-1.29; p = 0.192; PSM analysis: sHR 1.12; 95% CI 0.92-1.36; p = 0.248). However, ACEI/ARB use was associated with a significant reduction in HF admission rates in patients with LVEF ≤ 40% (univariate analysis: HR 0.70; 95% CI 0.56-0.88; p = 0.003; IPW adjusting analysis: HR 0.64; 95% CI 0.50-0.83; p = 0.001; PSM analysis: HR 0.65; 95% CI 0.46-0.92; p = 0.014). CONCLUSION Among hospitalized survivors of AMI, the use of ACEIs/ARBs was associated with a lower risk of follow-up HF in patients with LVEF ≤ 40% but not in those with LVEF > 40%. Further prospective studies are needed to confirm our results.
Collapse
Affiliation(s)
- María Cespón-Fernández
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain.
| | - Sergio Raposeiras-Roubín
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Emad Abu-Assi
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | | | - Pedro Flores-Blanco
- Cardiology Department, University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
| | - Cristina Barreiro-Pardal
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - María Castiñeira-Busto
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Isabel Muñoz-Pousa
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Elena López-Rodríguez
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Berenice Caneiro-Queija
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Rafael Cobas-Paz
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Saleta Fernández-Barbeira
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Pablo Domínguez-Erquicia
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | | | - Ángel López-Cuenca
- Cardiology Department, University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
| | - Miriam Gómez-Molina
- Cardiology Department, University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
| | - José Antonio Baz-Alonso
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | - Francisco Calvo-Iglesias
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| | | | - Andrés Íñiguez-Romo
- Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain
| |
Collapse
|
5
|
Abstract
Open-heart surgery has become a common procedure. Postcardiac surgery management is a critical issue and represents a crucial period in terms of physical recovery. Cardiac rehabilitation is increasingly considered as an integral component of the continuum of care for patients with cardiovascular disease. Its usefulness is now widely accepted, and therefore, it is recommended in most contemporary cardiovascular clinical practice guidelines. Similarly, early pharmacological management can modulate the pathophysiological alterations after cardiac surgery, leading to an improvement in the early and long-term outcome. In this review, we will present recent advances in postcardiac surgery management, focusing on the pathophysiology of the perioperative period and on recent evidences in pharmacological and rehabilitative strategies.
Collapse
|
6
|
Alassar A, Bazerbashi S, Easto R, Unsworth-White J. Which patients should be on renin-angiotensin system blockers after coronary surgery? Interact Cardiovasc Thorac Surg 2014; 19:667-72. [PMID: 24997188 DOI: 10.1093/icvts/ivu211] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'which patients should be on renin-angiotensin system blockers after coronary surgery?' Using the reported search, 12 papers represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The 12 studies included 5 prospective randomized controlled trials (RCTs) and 1 meta-analysis. One RCT of 2553 stable patients post-coronary artery bypass surgery (CABG) with left ventricular (LV) ejection fraction ≤40% showed that angiotensin-converting enzyme inhibition (ACEI) therapy can and probably should be delayed beyond 7 days due to increased cardiovascular morbidity and mortality associated with immediate postoperative initiation of ACEI treatment. Another study showed that the cardioprotective benefits of ACEI following CABG are persistent with respect to an LV ejection fraction below or above 40% and whether percutaneous coronary intervention (PCI) or CABG was performed. A large multicentre international study of 4224 patients undergoing CABG looking at a composite outcome of rates of cardiac, cerebral and renal events and in-hospital mortality showed that continuous treatment with ACEI compared with no ACEI was associated with reductions of risks of non-fatal events (P = 0.009, odds ratio 0.69, 95% confidence interval 0.52-0.91). Addition of ACEI de novo following surgery was also associated with significant reduction in the risk of the composite outcome (P = 0.004) and of a cardiovascular event (P = 0.04). We conclude that angiotensin-converting enzyme inhibitor treatment plays an important role in minimizing ischaemic events after CABG even in low-risk patients. The cardioprotective benefits of these drugs are persistent at mid- and long-term follow-up, with respect to LV ejection fraction below or above 40% and whether PCI or CABG was performed. Not only continuation of angiotensin-converting enzyme inhibition early after surgery but also adding ACEI de novo postoperatively can be associated with better cardiovascular and renal outcomes.
Collapse
Affiliation(s)
- Aiman Alassar
- Department of Cardiothoracic Surgery, Derriford Hospital, Plymouth, UK
| | - Samer Bazerbashi
- Department of Cardiothoracic Surgery, Derriford Hospital, Plymouth, UK
| | - Rachel Easto
- Department of Cardiothoracic Surgery, Derriford Hospital, Plymouth, UK
| | | |
Collapse
|
7
|
Fox KM, Bertrand ME, Remme WJ, Ferrari R, Simoons ML, Deckers JW. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J 2007; 153:629-35. [PMID: 17383303 DOI: 10.1016/j.ahj.2007.01.032] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2006] [Accepted: 01/16/2007] [Indexed: 01/14/2023]
Abstract
BACKGROUND The aim of the study was to assess the effect on cardiac events of adding perindopril 8 mg once daily to standard preventive therapy in the subgroup of EUROPA patients with previous revascularization and without previous myocardial infarction (MI). METHODS We conducted a subgroup analysis of the EUROPA study patients according to their revascularization and previous MI history. Among the 12,218 patients of EUROPA, we identified 6709 (54.9%) patients who had a previous revascularization. Approximately equal proportions had undergone percutaneous coronary intervention (3122) or coronary artery bypass grafting (3136). Of the revascularized patients, 3047 (24.9%) patients had not experienced a previous MI. RESULTS Out of the 6709 revascularized patients, 3340 were treated with perindopril and 3369 with placebo. Baseline characteristics were similar to the whole EUROPA population in terms of demographics, medical history, physical examination (heart rate, blood pressure), and medications at screening. The mean patient age was 60 years, and 85% were men. The relative risk reduction with perindopril 8 mg was 17.3% (95% CI 1.3%-30.8%, P = .035) for the composite primary end point of cardiovascular death, nonfatal MI, and resuscitated cardiac arrest and was 23% (95% CI 4.9%-37.6%, P = .015) for fatal and nonfatal MI. In the 3047 revascularized patients without a history of MI, perindopril was associated with a relative risk reduction of 31.7% for fatal and nonfatal MI (95% CI 4.4%-51.2%, P = .026). CONCLUSION Perindopril 8 mg daily is beneficial for primary and secondary prevention of cardiac events in patients with coronary artery disease without clinical evidence of heart failure including those with previous revascularization.
Collapse
Affiliation(s)
- Kim M Fox
- Cardiology Department, Royal Brompton Hospital, Sydney Street, London, UK.
| | | | | | | | | | | |
Collapse
|
8
|
Abdulla J, Barlera S, Latini R, Kjoller-Hansen L, Sogaard P, Christensen E, Kober L, Torp-Pedersen C. A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007; 9:129-35. [PMID: 16829187 DOI: 10.1016/j.ejheart.2006.05.002] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2005] [Revised: 03/27/2006] [Accepted: 05/03/2006] [Indexed: 10/24/2022] Open
Abstract
BACKGROUND AND AIM To summarize and quantify results of echocardiographic studies examining the effect of angiotensin converting enzyme (ACE) inhibition on left ventricular remodelling in patients with acute myocardial infarction (MI) and in patients with left ventricular systolic dysfunction (LVSD). METHODS Systematic review of the literature and meta-analysis of eligible studies providing data on end-diastolic and end-systolic volumes and left ventricular ejection fraction (LVEF) were performed. RESULTS Data from 16 eligible studies were meta-analysed. The results of studies including patients with MI and preserved LVEF (>45%) showed no significant benefit of ACE inhibition. Results of studies/subgroups with mean LVEF < or =45% demonstrated significant differences in diastolic and systolic volumes of 3.0 (0.1, 6.0) ml and 2.25 (0.04, 4.4) ml in short-term (4-14 weeks) follow-up in favour of ACE inhibitor, p=0.041 and p=0.046 respectively. In the long-term (6-12 months) follow-up, the differences in diastolic and systolic volumes were 4.2 (0.98, 7.4) ml and 3.3 (0.9, 5.8) ml in favour of ACE inhibitor, p=0.01 and p=0.007 respectively. LVEF improved in both short and long-term follow-up, p=0.034 and p=0.021, respectively. CONCLUSION Chronic use of ACE inhibition has a small but sustained and beneficial effect on remodelling in patients with myocardial infarction and patients with chronic left ventricular dysfunction.
Collapse
Affiliation(s)
- Jawdat Abdulla
- Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark.
| | | | | | | | | | | | | | | |
Collapse
|